Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

NCT06061146 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

136

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Arm A
DRUG: Arm A
RADIATION: Arm A
DRUG: Arm B
RADIATION: Arm B

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]